Cara Therapeutics, Inc. (NASDAQ:CARA) headquartered in Stamford, will host a conference call for the investment community to discuss the 2Q20 earnings result on 10th August 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.caratherapeutics.com
Earnings Expectation
Cara Therapeutics, Inc. is reporting second quarter financial results on Monday 10th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, CARA is expected to report 2Q20 loss of $ 0.67 per share from revenue of $ 5.06 million.
For the full year, analysts anticipate top line of $ 21.87 million, while looking forward to loss of $ 2.61 per share bottom line.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the bodys peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus.
